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Objective: Mesenchymal stem cells isolated from adipose tissue (ASC) have been 
shown to influence the course of osteoarthritis (OA) in different animal models and are 
promising in veterinary medicine for horses involved in competitive sport. The aim of 
this study was to characterize equine ASCs (eASCs) and investigate the role of inter-
feron-gamma (IFNγ)-priming on their therapeutic effect in a murine model of OA, which 
could be relevant to equine OA.
Methods: ASC were isolated from subcutaneous fat. Expression of specific markers was 
tested by cytometry and RT-qPCR. Differentiation potential was evaluated by histology 
and RT-qPCR. For functional assays, naïve or IFNγ-primed eASCs were cocultured with 
peripheral blood mononuclear cells or articular cartilage explants. Finally, the therapeutic 
effect of eASCs was tested in the model of collagenase-induced OA (CIOA) in mice.
results: The immunosuppressive function of eASCs on equine T cell proliferation and 
their chondroprotective effect on equine cartilage explants were demonstrated in vitro. 
Both cartilage degradation and T cell activation were reduced by naïve and IFNγ-primed 
eASCs, but IFNγ-priming enhanced these functions. In CIOA, intra-articular injection of 
eASCs prevented articular cartilage from degradation and IFNγ-primed eASCs were 
more potent than naïve cells. This effect was related to the modulation of eASC secre-
tome by IFNγ-priming.
conclusion: IFNγ-priming of eASCs potentiated their antiproliferative and chondropro-
tective functions. We demonstrated that the immunocompetent mouse model of CIOA 
was relevant to test the therapeutic efficacy of xenogeneic eASCs for OA and confirmed 
that IFNγ-primed eASCs may have a therapeutic value for musculoskeletal diseases in 
veterinary medicine.
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inTrODUcTiOn
Osteoarthritis (OA), also known as degenerative joint disease, is 
of major concern for human health. It is also one of the most 
common orthopedic problems seen in horses. Clinical signs of 
disease are lameness, joint swelling, pain on flexion, or reduced 
activity, and, with time, these symptoms lead to structural joint 
alterations. Degradation of articular cartilage is a consequence 
of its poor capacity to repair and to withstand the cyclic trauma 
of athletic activity, and this is exacerbated with aging. Current 
treatments to control inflammation and pain and to stop disease 
progression include systemic non-steroidal anti-inflammatory 
drugs (NSAIDs), intra-articular steroids, viscosupplementation, 
and chondroprotectants (1, 2). A combination of therapies is 
frequently used to have an additive or synergistic response to 
injury. However, although no adverse effect has been reported, 
these approaches would deserve extensive controlled studies to 
demonstrate efficacy and superiority over unique treatments 
for precise indications. More recently, the economic impact of 
musculoskeletal disorders on the horse industry has stimulated 
many commercial companies to offer stem cell-based regenera-
tive therapies for veterinary purposes (3).
Multipotent mesenchymal stem or stromal cells (MSCs) 
isolated from bone marrow (BM) or adipose tissue (AT) are the 
most extensively studied stem cells (4). Techniques for isolating 
and characterizing equine MSCs (eMSCs) have evolved based on 
those described for human MSCs (5–8). The main therapeutic 
applications of MSCs in equine practice are principally for tend-
initis and ligament lesions, but OA lesions have become a major 
challenge. Intra-articular injection of eMSCs or BM concentrates 
for treatment of OA or cartilage defects has already proved safety 
with no adverse effect reported (9–11). Interestingly, eMSCs from 
umbilical cord Wharton’s jelly were shown to be effective in a 
xenogeneic model of rabbit mild OA (12). However, efficacy of 
eMSC injection for OA remains controversial with some studies 
demonstrating molecular [increase of collagen and glycosami-
noglycan (GAG) content] and functional improvement (11, 13), 
while others showing no clinical benefit (14–16).
Mesenchymal stem or stromal cell-based therapy for OA treat-
ment has shown significant results in other animal models [for 
review, see Ref. (17)]. Moreover, allogeneic or xenogeneic MSCs 
exert a therapeutic effect similar as syngeneic MSCs, and survival 
of xenogeneic adipose-derived MSC (ASCs) is not affected by 
OA environment as compared with healthy environment (18). 
A majority of studies indeed reports engraftment and function 
of MSCs across the species barrier with evidence of failure to 
function in only 6.4% of evaluated cases (19). In the different 
preclinical models of OA, the anti-inflammatory property of 
MSCs is thought to have a major role (20–23). Indeed, in vivo, 
it was reported that synovial activation rapidly drives anti-
inflammatory and protective effects of intra-articularly injected 
ASCs, which is reflected by decreased S100A8/A9 alarmins 
levels (24). We previously showed that MSCs secrete factors that 
protect OA chondrocytes from hypertrophy, dedifferentiation, 
inflammation, and apoptosis (25, 26). In addition, MSCs need 
to be activated to be chondroprotective since their conditioned 
media do not have any effect on chondrocyte phenotype (27). 
Demonstration that MSCs require priming for exerting an immu-
nosuppressive function and be more actively recruited has been 
clearly shown in humans (28, 29). Pre-activation of MSCs occured 
in presence of interferon-γ (INFγ) and/or tumor necrosis factor 
(TNF)-α, interleukin (IL1)-α or IL1-β (30), and enhanced their 
anti-inflammatory effect without influencing their differentiation 
capacities (31).
While the need for a better evaluation of the functional role of 
eMSCs using in vitro assays is obvious, the possibility to activate 
the cells for improving their therapeutic effect has not been 
tested in OA. So, the aims of this study were first to examine the 
effect of IFNγ-pretreatment on the anti-inflammatory properties 
of equine ASCs (eASCs) in vitro and on the chondroprotective 
effect of eASCs on cartilage explants and, second, to understand 
the mechanism of action of eASCs by gene analysis. Finally, the 
efficacy of IFNγ-pretreated eASCs in OA was evaluated after a 
single intra-articular injection in the xenogeneic murine model 
of collagenase-induced OA (CIOA).
MaTerials anD MeThODs
isolation and culture of asc
Equine ASCs were isolated from subcutaneous AT from the 
horse hip and obtained during surgery by veterinary doctors on 
tranquilized horses. The protocol was approved by the Ethical 
Committee of VetAgro Sup (permit number: 69 127 800, certi-
fied number: B 69 127 0501). AT was cut into small pieces and 
digested with 250 U/mL type 1 collagenase (Worthington, Serlabo 
Technologies, Entraigues) at 37°C for 1.5 h. The stroma vascular 
fraction was collected by centrifugation (300 g, 10 min), and cells 
were filtered successively through a large sterile filter and, then, 
through 100 and 70 μm porous membranes (Cell Strainer, BD 
Biosciences, Le Pont de Claix). Erythrocytes were lysed using 
red lysis buffer (NH4Cl 155 mmol/L, KHCO3 10 mmol/L, EDTA 
0.11  mmol/L, pH 7.3). Cell counting and viability were evalu-
ated with calibrated Vicell Beckman Coulter. Cells were plated 
as passage 0 at the initial density of 4000  cells/cm2 in αMEM 
GlutaMAX™ (ThermoFisher Scientific, Illkirsch) supplemented 
with 100 U/mL penicillin, 100 mg/mL streptomycin, 10 μg/mL 
gentamicine/0.25 μg/mL amphotericin B (ThermoFisher scien-
tific), 10% fetal calf serum (FCS, ThermoFisher scientific), and 
1  ng/mL basic fibroblast growth factor (bFGF; Sigma-Aldrich, 
Saint-Quentin-Fallavier). After 1 week, cells were trypsinized and 
expanded at 2000 cells/cm2 till day 14, where ASCs at passage 1 
were used. For IFNγ priming, 100 ng/mL of equine IFNγ (R&D 
Systems, Lille) was added in the culture medium for 24 h before 
use of the cells. mMSC were isolated from BM of C57BL/6 mice 
and characterized, as previously described (21).
Flow cytometry analysis
Equine ASCs (200,000  cells) in PBS containing 0.2% bovine 
serum albumin (BSA) were incubated with different antibodies: 
non-conjugated ELA-class I (clone CVS22, AbD Serotec, Bio-
Rad, Marnes-la-Coquette) or -class II (clone CVS20, Bio-Rad) 
primary antibodies coupled with Alexa Fluor 488 second-
ary antibody, PE-conjugated CD29 (clone 4B4LDC9LDH8, 
Beckman Coulter), CD44 (clone CVS18, Bio-Rad) or CD90 
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(clone 5E10, Bio-Rad), or the respective isotype control (clone 
MOPC-21, Bio-Rad) at room temperature for 60 min in the dark. 
The labeled cells were then analyzed by multiparameter flow 
cytometry using a LSR II cytometer and the BD FACSDiva™ 
software V.6.1.3 (BD Biosciences).
Differentiation of eascs
Adipogenic differentiation was induced after plating eASCs at 
the density of 1500 cells/cm2 in proliferative medium for 7 days. 
Medium was changed by adipogenic medium (DMEM-F12, 
100  U/mL penicillin, 100  μg/mL streptomycin, 15% Rabbit 
Serum, 1 μM dexamethasone, 60 μM indomethacin, 10 μg/mL 
insulin, 0.5 mM IBMX), for 21 days. Adipogenesis was assessed by 
quantification of adipocyte markers by RT-qPCR, and lipid drop-
lets were visualized by HCS LipidTOX™ Green neutral lipid stain 
(ThermoFisher Scientific). Osteogenesis was induced by culture 
at low density (1500 cells/cm2) in osteogenic medium (DMEM, 
10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 mM 
ascorbic acid, 0.1 μM dexamethasone) for 21 days. Osteogenic dif-
ferentiation was assessed by quantification of osteoblast markers 
by RT-qPCR and extracellular matrix mineralization detected by 
alizarin red S staining. Chondrogenic differentiation was induced 
by pelleting and culturing eASCs (250,000  cells/tube) in chon-
drogenic medium {high glucose DMEM, 0.1 μM dexamethasone, 
1  mM sodium pyruvate, 170  μM ascorbic-2-phosphate acid, 
0.35  mM proline, ITS [insulin/transferrin/selenic acid (Lonza, 
Koln, Germany)], 10  ng/mL human TGF-β3}. Chondrogenesis 
was assessed by quantification of chondrocyte markers by 
RT-qPCR and Safranin O–Fast green staining.
rT-qPcr
Total RNA was extracted from cells using the RNeasy kit (Qiagen, 
Courtaboeuf). RNA (500 ng) was reverse transcribed using the 
M-MLV enzyme (ThermoFisher Scientific). qPCR, for evaluat-
ing eASC differentiation, was performed using MSC PCR array 
(Qiagen). Analysis of cytokine expression was done using horse 
cytokines and chemokines RT2 profiler PCR array (Qiagen). 
Other qPCR analyzes were done with Taqman gene expression 
assay (Life Technologies, Courtaboeuf). PCR reactions were 
carried out on 20 ng of cDNA samples according to supplier’s rec-
ommendations on a 7500 FAST real-time PCR system (Applied 
Biosystems) and analyzed with the dedicated software. All values 
were normalized to GAPDH housekeeping gene and expressed as 
relative expression or fold change using the respective formulae 
2−ΔCT or 2−ΔΔCt.
equine PBMc isolation and 
Proliferative assay
Equine peripheral blood mononuclear cells (PBMC) were 
collected from adult allogeneic horses into EDTA-containing 
tubes via jugular venipuncture. Mononuclear cells were 
isolated from peripheral blood by Ficoll density gradient 
centrifugation (density 1.077  g/L; Sigma) and suspended in 
IMDM GlutaMAX™ medium (ThermoFisher Scientific) 
supplemented with 10% inactivated FCS, 2  mM glutamine, 
100  U/mL penicillin, 100  μg/mL streptomycin, 0.1  mM non-
essential amino acids, 1 mM sodium pyruvate, 20 mM HEPES 
(N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid), and 
5  ×  10−5M 2-mercaptoethanol. eASCs were plated in 96-well 
flat-bottom plates at different densities (105, 104, 103, or 102 cells/
well) ± 100 ng/mL equine recombinant INFγ (R&D Systems) at 
37°C for 24 h with 5% CO2. PBMCs were added at 105 cells/100 μL/
well, and proliferation was induced by adding the mitogen phyto-
hemaglutinin (PHA) at 5 μg/mL (Sigma-Aldrich). Unstimulated 
PBMCs were used as negative control. After 4 days incubation, 
cultures were pulsed with 5 μCi/mL 3H thymidine (Amersham, 
Buckinghamshire, UK) for 18  h. PBMCs were harvested and 
thymidine incorporation was expressed as proliferation in counts 
per minute. The inhibitory effect of eASCs on PBMC prolifera-
tion was quantified by subtracting the signal for PHA-stimulated 
PBMCs from unstimulated PBMCs. Proliferation rate was cal-
culated referring to 100% the value of PHA-stimulated PBMCs.
cartilage explant culture
Fetlock joints were recovered from the local slaughter house. The 
joints were aseptically opened with a scalpel in a dissection room 
to allow access to articular cartilage. Joints were graduated given 
the OARSI grade (32), and grade 1 joints were selected. A biopsy 
punch was used to extract 3  mm3 explants (average weight of 
10 mg) from cartilage. Five explants per well in 24 multi-well plates 
were cultured in 1 mL of explant culture medium (DMEM, 20 mM 
Hepes, 5 μg/mL ascorbic acid, ITS, 1% Gentamycin) and incubated 
at 37°C, in 5% CO2 humidified atmosphere. After 2 days, recombi-
nant equine IL-1β (1 ng/mL; R&D Systems, Lille) and recombinant 
human oncostatin M (10 ng/mL; Invitrogen, Courtaboeuf) were 
added in the culture medium, and explants were cultured with or 
without 25,000 or 100,000 eASCs on a transwell membrane (pore 
0.4 μm) during 7, 9, or 12 days. eASCs were primed or not with 
equine IFNγ (100 ng/mL) for 24 h before addition to the explant 
cultures. Media were changed every 2–3  days and aliquots of 
supernatants were stored at −20°C until GAG quantification.
glycosaminoglycan Quantification
Glycosaminoglycan quantification was performed using 
Blyscan™ GAG Kit on triplicate wells following supplier’s recom-
mendations (Tebu-Bio, Le Perray en Yvelines).
collagenase-induced Osteoarthritis 
Mouse Model
Collagenase-induced OA was induced as previously described 
(18). Animal experimentation was conducted in agreement with 
the Languedoc-Roussillon Regional Ethics Committee on Animal 
Experimentation (approval CEEA-LR-10041). All surgery was 
performed under isoflurane gas anesthesia, and all efforts were 
made to minimize suffering. Briefly, right knee joints of mice 
were injected with 1  U type VII collagenase from Clostridium 
histolyticum (Sigma-Aldrich) in 5 μL of saline at day 0 and day 
2, causing disruption of the ligaments and local instability of the 
joint. Groups of 10 mice received at day 7, either saline, mMSC 
(2 × 105 cells/8 μL), or eASCs [2 × 104 or 2 × 105 cells/8 μL primed 
or not with IFNγ (100 ng/mL for 24 h)]. Mice were sacrificed at 
day 42, and the joints were collected, fixed in 4% formalin for 
1 week, decalcified in 5% formic acid for 2 weeks, and embedded 
in paraffin. Knee frontal sections (three sections separated from 
FigUre 1 | characterization of equine ascs. (a) Representative 
photomicrograph of eASCs. (B) Percentage of eASCs positive for the 
indicated membrane markers. Results are percentage of positive cells and 
are expressed as mean ± SEM for three separate experiments. (c) Gene 
expression level of indicated markers in eASCs. Results are relative 
expression (2−ΔCT) and are expressed as mean ± SEM for three separate 
experiments. (D) Differentiation of eASCs: adipogenesis is characterized by 
the expression of peroxysome proliferator-activated receptor (PPAR)-γ at day 
21 (d21) versus d0 and by the visualization of lipid droplets stained with HCS 
LipidTOX™ Green neutral lipid stain and counterstained with DAPI (lower 
panel) versus control proliferative medium (upper panel) at d21 (scale bar is 
25 μm). Osteogenesis is characterized by the expression of Runx2 at d21 
versus d0 and by Alizarin Red S positive staining in differentiation versus 
proliferative medium at d21 (scale bar is 100 μm). Chondrogenesis is 
characterized by the expression of Sox9, collagen IIA1 (col IIA1), and 
aggrecan (Agg) at d21 versus d0 and by Safranin O staining (lower panel) 
versus undifferentiated control (upper panel) at d21 (scale bar is 100 μm). 
Results are expressed as relative expression (2−ΔCT) and represented as 
mean ± SEM for three to six independent biological replicates. Data were 
analyzed using the Mann–Whitney test. *p < 0.05. ND: not detected.
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140 μm) were cut and stained with Safranin O–Fast Green stain-
ing. Histological OA score was determined using the modified 
Pritzker OARSI score (32). At euthanasia, blood was collected by 
intracardiac puncture, centrifuged at 1000g during 10 min. Sera 
were recovered and stored at −20°C.
serum cytokine Quantification
Quantification of murine IL1β, IL6, IL10, osteoprotegerin 
(OPG) and prostaglandin E2 (PGE2) (R&D Systems), CTX2 
(ImmunoDiagnostic Systems, Pouilly en Auxois), and cartilage 
oligomeric matrix protein (COMP) (MD Bioproducts, Zürich) 
was performed in sera by specific enzyme-linked immunosorb-
ent assays (ELISA) as recommended by the suppliers.
statistical analysis
Data were expressed as the mean  ±  SEM. Statistical analysis 
was performed with GraphPad Prism software. The comparison 
between the different groups was analyzed by one-way analysis 
of variance (ANOVA) followed by Dunnett post hoc test, when 
data were parametric, or by a Kruskal–Wallis test, when the data 
distribution was not Gaussian. Comparison between two groups 
was analyzed with a Mann–Whiney test for non-parametric data. 
The test used was indicated in the figure legends. A p value <0.05 
was considered significant.
resUlTs
Phenotype and Differentiation Properties 
of eascs
Equine ASCs isolated from subcutaneous AT exhibited a classic 
fibroblastic morphology at passage 1 (Figure 1A). The majority 
of cells were positive for CD29, CD44, CD90, and ELA class I 
markers and negative for ELA class II as detected by flow cytom-
etry (Figure 1B). In absence of available antibodies, expression 
of ASC markers CD34, CD73, and CD105 was confirmed at the 
mRNA level, while CD45 hematopoietic and von Willebrand fac-
tor (vWF) endothelial markers were not detected (Figure 1C). 
Under adipogenic conditions, eASCs stored triglycerides in 
lipid droplets as shown by HCS LipidTOX™ Green neutral lipid 
staining and the expression of the transcription factor regulat-
ing adipogenesis PPARγ, which was significantly increased after 
21 days of differentiation compared to day 0 (Figure 1D). eASCs 
differentiated into osteoblasts, as shown by Alizarin Red S stain-
ing and increased Runx2 expression at day 21 (Figure 1D). They 
also differentiated toward chondrocytes, as suggested by the 
presence of sulfated GAG evidenced by Safranin O staining and 
demonstrated by an enhanced expression of Sox9, Aggrecan, and 
Collagen type II markers (Figure  1D). These results indicated 
that eASCs possess all the characteristics of mesenchymal stem 
cells (33).
effect of iFnγ Pretreatment on 
immunosuppressive and 
chondroprotective Properties of eascs
With the rationale in mind that priming eASCs will improve their 
immunosuppressive properties, we evaluated their capacities to 
inhibit the proliferation of ePBMCs. eASCs were pretreated or 
not with IFNγ for 24  h and then cultured with PHA-activated 
ePBMCs at different ratios for 3  days. When compared with 
ePBMCs alone, both eASCs- and IFNγ-primed eASCs were 
able to inhibit T cell proliferation in a dose-dependent manner 
(Figure 2A). The antiproliferative effect of IFNγ-primed eASCs 
FigUre 2 | iFnγ-priming improves the immunosuppressive and 
chondroprotective properties of eascs in vitro. (a) Proliferation of 
equine PBMCs in presence of naïve eASCs or IFNγ-primed eASCs at 
different ratios. Results are expressed as the percentage of PHA-induced 
proliferation of equine PBMCs, which was assigned the value of 100% and 
represented as mean ± SEM for three independent biological replicates. 
(B) Gene expression level of TGFβ1, COX-2, and IL-6 in eASCs. Gene 
expression in IFNγ-primed eASCs was normalized to that obtained in naïve 
eASCs. (c) PGE2 concentration in supernatants of naïve and IFNγ-primed 
eASCs. (D) GAG release quantification from cartilage explants incubated with 
IL1β (1 ng/mL) and Oncostatin M (10 ng/mL) during 7, 9, or 12 days and 
cocultured with or without 25,000 or 100,000 naïve and IFNγ-primed eASCs 
(100 ng/mL, 24 h before coculture). Results are expressed as the percentage 
of GAG release normalized to control condition (explant alone) at each time 
points and represented as mean ± SEM for 10–14 independent biological 
replicates. Data were analyzed using the Kruskal–Wallis test followed by 
Dunn’s test for multiple comparisons for (a, D) and using the Mann–Whitney 
test for (B,c) *p < 0.05 in samples versus PBMC alone (a) or control (D); 
#p < 0.05 between primed and unprimed samples.
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was, however, significantly higher, whatever the eASC/ePBMC 
ratio. In order to determine whether this higher suppressive effect 
of IFNγ-primed eASCs was related to higher paracrine functions, 
expression of several known immunosuppressive mediators was 
quantified by RT-qPCR. We noticed that TGFβ1 expression levels 
were decreased in IFNγ-primed eASCs, while IL6 expression 
was increased (Figure 2B). No change in expression of COX-2 
transcripts or PGE2 secretion was observed (Figures 2B,C).
In parallel, we investigated whether eASCs could exert chon-
droprotective properties and inhibit cartilage degradation in an 
in vitro model of OA cartilage. We used equine cartilage biopsies 
cultured with IL1β and Oncostatin M for 12 days to induce carti-
lage degradation. Cartilage destruction was evaluated by quanti-
fying GAG release in the culture medium. In order to determine 
the effect of eASCs on cartilage degradation, a coculture assay 
was designed using a transwell system to avoid eASCs–cartilage 
contact. Cartilage explants (in the lower part) were cultured with 
2.5 ×  104 or 105 naïve or IFNγ-primed eASCs (upper part). In 
these conditions, naïve eASCs did not exert a protective effect on 
cartilage degradation, even though a significant decrease of GAG 
release was observed with the dose of 105 eASCs after 9 days of 
coculture (Figure 2D). By contrast, the two doses of IFNγ-primed 
eASCs significantly reduced GAG release at the three time points. 
Interestingly, IFNγ-primed eASCs tended to be more efficient at 
the lowest dose as compared with the highest dose, but the differ-
ence was not significant. Altogether, our data demonstrated that 
IFNγ-priming of eASCs enhanced their immunosuppressive and 
chondroprotective function.
effect of eascs in a Xenogeneic Mouse 
Model of Oa
We, then, investigated whether eASCs could exert a therapeutic 
effect in vivo using a xenogeneic relevant model of OA. We used 
the CIOA mouse model which is characterized by moderate 
inflammation of the synovial membrane, osteophyte formation, 
and cartilage degradation (18). First, we evaluated the effect of 
intra-articular injection of eASCs (2 ×  105  cells) on knee joint 
OA score by comparison with mMSCs (2 × 105 cells). Histological 
analysis of knee joint sections revealed protection against carti-
lage degradation in animals treated either with mMSCs or eASCs 
as compared with the CIOA control group (Figure 3A). Cartilage 
protective effect of mMSCs and eASCs was confirmed by scoring 
both femoral condyles and tibial plateaux in the lateral and medial 
compartments (Figure 3B). Significantly, lower mean OA scores 
were obtained after eASCs or mMSCs treatment, and OA score 
of the eASC group was highly significant compared to control 
group. These results confirmed that the CIOA mouse model was 
effective for evaluation of the effect of xenogeneic eASC injection 
on OA symptoms.
We, therefore, compared the effect of naïve and IFNγ-primed 
eASCs on OA progression. Injection of a high dose of eASCs 
(2 ×  105  cells) significantly improved the OA score, while the 
low dose (2 × 104 eASCs) had no effect (Figure 4A). By contrast, 
both doses of IFNγ-primed eASCs reduced the OA score, but 
only the lowest dose of IFNγ-primed eASCs induced a signifi-
cant decrease. Of importance, 2 × 104 IFNγ-primed eASCs were 
FigUre 3 | Xenogeneic eascs improve Oa scores in the collagenase-induced Oa mouse model. OA was induced by intra-articular injection of 
collagenase in mouse knee joints and the severity of OA was evaluated at day 42. (a) Representative photographs of knee joints from control (collagenase alone) 
(upper), mMSCs-treated (middle), and eASCs-treated (lower) mice. (B) Histological OA score of tibia plateaus and femur condyles in the mouse knee joints and 
mean at euthanasia. Results are expressed as the mean ± SEM, n = 10. Data were analyzed using the Kruskal–Wallis test followed by Dunn’s test for multiple 
comparisons. *p < 0.05.
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as efficient as 2 ×  105  naïve eASCs to protect cartilage from 
degradation. The therapeutic effect of eASCs was confirmed by 
measuring the level of OPG, a bone metabolism marker, in the 
sera of mice at euthanasia. It was significantly decreased in mice 
treated with 2 × 104 IFNγ-primed eASCs (Figure 4B). Levels of 
COMP, a marker of cartilage turnover, did not change in the sera 
of treated mice compared with control group (Figure 4C), and 
IL6, IL10, IL1β, and C-terminal cross-linked telopeptide of type 
II collagen (CTX2) were not detected in the sera of mice (data 
not shown).
Finally, we evaluated whether naïve or IFNγ-primed eASCs 
could inhibit murine T cell proliferation since the CIOA mouse 
model is known to be associated with local moderate inflam-
mation. We, therefore, tested naïve and IFNγ-primed eASCs 
on murine splenocytes in a proliferative assay. Both eASCs sig-
nificantly decreased splenocyte proliferation in a dose-dependent 
manner, and this inhibitory effect was higher with IFNγ-primed 
eASCs at the lowest ratios of eASCs/splenocytes (Figure  4D). 
These data suggested that the effect of eASCs in  vivo could be 
mediated at least in part by their inhibitory role on inflammatory 
cells. Overall, we present evidence that eASCs were efficient to 
reduce the clinical score of OA in the xenogeneic CIOA model, 
and IFNγ-pretreatment increased their immunosuppressive and 
chondroprotective functions.
effects of iFnγ Priming on the cytokine 
Profile of eascs
In order to understand the effect of IFNγ priming on the immu-
nosuppressive properties of eASCs, a gene expression analysis was 
performed on 89 genes related to cytokine or chemokine families. 
Hierarchical clustering analysis revealed that the gene expression 
pattern of IFNγ-primed eASCs greatly differed from that of naïve 
eASCs (Figure 5A). IFNγ priming modified the transcriptomic 
program of eASCs by significantly dysregulating 13 genes. Gene 
expression of CXCL9, CXCL11-like, IL32-like, and CXCL10 was 
significantly induced in IFNγ-primed eASCs compared with 
naïve eASCs (Figure 5B). In parallel, gene expression of CSF1, 
IL6, IL7-like, IL-15, CCL2, CCL13, and TNFS13B was signifi-
cantly upregulated in IFNγ-primed eASCs, while expression of 
TNFSF11-like and TGFβ2-like was downregulated as compared 
with naïve eASCs (Figure 5C). Indeed, the cytokine/chemokine 
profile of eASCs was dramatically altered by IFNγ priming.
DiscUssiOn
The present study demonstrated the feasibility of using a mouse 
OA model for assessing the efficacy of eASC-based therapy 
and developing eASC pretreatment strategies to enhance their 
 therapeutic potential.
Equine athletes are subject to a number of musculoskeletal 
injuries, some of which will lead to degenerative joint diseases. 
The lack of effective treatment to stop disease progression causes 
horses to retire early from competition. The current challenge is, 
therefore, to find a treatment allowing sport horses to keep or 
increase their athletic level. However, evaluating the effectiveness 
of novel therapies in an equine model of OA is time and cost 
consuming. The possibility to rely on a small-animal model that 
is relevant for reproducing the main characteristics of the disease 
should allow the optimization of the optimal doses, timings, and 
pretreatment options in a rapid prescreening step for further 
upgrading to larger animals.
Because the main effect of ASCs in OA seems to be related 
to their anti-inflammatory functions (17), the choice of the 
mouse model to be used for evaluating eASC efficacy is of 
importance. Indeed, local administration of murine ASCs 
after destabilization of medial meniscus (DMM) model had no 
effect on OA pathology (24). By contrast, murine ASC treat-
ment was shown to be efficient in the CIOA model, which is 
FigUre 4 | iFnγ-primed eascs improve Oa score. (a) OA score for tibia plateaus and femur condyles in the knee joint and mean at euthanasia. Results are 
expressed as the mean ± SEM, n = 10. (B) Osteoprotegerin (OPG) and (c) cartilage oligomeric matrix protein (COMP) concentrations were determined in sera of 
mice at euthanasia by specific sandwich enzyme-linked immunosorbent assay (ELISA). Results are expressed as the mean ± SEM, n = 10. (D) Proliferation of 
murine splenocytes in presence of different ratios of naïve or IFNγ-primed eASCs. Results are expressed as the percentage of ConA-induced proliferation of 
splenocytes which was assigned the value of 100% and represented as mean ± SEM for three independent biological replicates. Data were analyzed using the 
Kruskal–Wallis test followed by Dunn’s test for multiple comparisons in A, B, and C and using ANOVA followed by a Dunnett’s test for multiple comparisons in D. 
*p < 0.05 or p = 0.07 compared samples with the control; #p < 0.05 compared samples with each other.
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characterized by a highly activated synovial lining containing 
inflammatory macrophages, and efficacy of ASCs was related 
to the degree of synovial activation (23, 24). In experimental 
models, synovitis was, therefore, shown to be essential to medi-
ate the anti-inflammatory function of ASCs. We confirmed in 
the present study the usefulness of the CIOA model to assess 
efficacy of ASC-based therapy in a xenogeneic approach as 
previously demonstrated with human ASCs (18). The feasi-
bility of using a xenogeneic model to investigate the role of 
eASCs in OA was also recently validated in another study. IA 
injection of eMSCs isolated from umbilical cord Wharton’s 
jelly partly prevented OA signs in the rabbit model of medial 
FigUre 5 | effect of iFnγ-priming on the inflammatory gene profile of 
eascs. Gene array analysis of inflammatory cytokines and chemokines 
mRNA compared naïve and IFNγ-primed eASCs. (a) Hierarchical clustering 
comparing naïve or IFNγ-primed eASCs, (B) induced gene expression levels 
in IFNγ-primed eASCs expressed as relative expression (2−ΔCT), 
(c) significantly modulated gene expression levels in IFNγ-primed eASCs. 
Results are represented as mean ± SEM for three independent biological 
replicates. Data were analyzed using the Mann–Whitney test. *p < 0.05.
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meniscal release (MMR). MSCs were shown to target the 
synovium by modulating the expression of matrix-degrading 
enzymes in favor of an anti-catabolic environment (12). The 
interest of using the mouse model of OA, however, is the cost 
effectiveness and the availability of various reagents or genetic 
models that allow easier evaluation of mechanisms of action. 
Furthermore, our results demonstrated that mice receiving 
eASCs did not develop any adverse effects confirming the safety 
of IA injection of xenogeneic ASCs for the treatment of OA 
(18). In addition, the CIOA mouse model could be useful to 
determine the potency of different batches of eASCs in vivo in 
terms of anti-inflammatory and chondroprotective functions. 
This could be of interest for veterinary stem cell companies, 
which already provide allogeneic eASC or eMSC banking, in 
order to evaluate donor cell variability.
Besides providing evidence that CIOA model is a suit-
able model to assess eASC therapy, the second objective of this 
study was to demonstrate the efficacy of IFNγ pretreatment for 
improving the therapeutic potential of eASCs. Priming of MSCs 
by inflammatory signals is required for their homing and anti-
inflammatory functions and could, therefore, enhance therapeu-
tic efficacy [for review, see Ref. (29, 34)]. Here, we demonstrated 
that IFNγ-pretreatment for 24 h improved the in vitro capacities 
of eASCs to inhibit the proliferation of T lymphocytes and to 
reduce the catabolic activity of chondrocytes. This effect could 
be explained by the modulation of the secretome, as evidenced at 
the gene expression level. Indeed, IFNγ-pretreatment induced or 
upregulated the expression of several chemokines, most notably 
CXCL9, CXCL10, and CXCL11, which are ligands for CXCR3, 
the T cell-specific chemokine receptor. The critical role of these 
chemokines in the immunosuppressive properties of MSCs 
was shown using neutralizing antibodies against CXCR3 that 
prevented the ability of MSCs to recruit leukocytes and inhibit 
their proliferation (30). Among upregulated cytokines, IL15 and 
IL6 also participate to the anti-inflammatory functions of MSCs. 
IL15 produced by MSCs has been shown to attract NK cells, 
alter their phenotype, suppress their proliferation and cytokine 
secretion ability, and decreased their cytotoxicity (35). IL6 has 
also been demonstrated to act on PGE2 secretion, neutrophil 
apoptosis, and macrophage and dendritic cells polarization 
toward a tolerogenic phenotype (21, 36). Gene expression 
analysis also evidenced TGFβ2 downregulation in IFNγ-primed 
eASCs. TGFβ2 is a known chondrogenic factor, but its expres-
sion is also related with the loss of immunosuppressive effect (37, 
38). The role of other up or downregulated mediators (IL32-like, 
CSF1, IL7-like, CCL2, CCL13, TNFS13B, TNFSF11-like) in the 
immunosuppressive potential of MSCs is less known but, in 
view of the high levels of upregulation after IFNγ-priming, these 
mediators warrant further investigation. All together, these data 
strongly suggest that IFNγ-priming of eASCs enhanced their 
immunosuppressive abilities and could reduce synovial inflam-
mation as observed in vivo.
Moreover, our results demonstrated that IFNγ-primed eASCs 
display protective effect on cartilage degradation in vitro, while 
naïve eASCs did not. These results are in concordance with 
previous data reporting that inflammatory signals enhanced 
the beneficial role of MSCs on OA chondrocytes. In a 2D 
coculture model, hASCs were shown to decrease the secretion 
of several inflammatory factors when chondrocytes from OA 
patients expressed high levels of inflammatory molecules, but 
not when chondrocytes were poorly inflammatory (25). In 
addition, conditioned media from unprimed hASCs did not 
impact chondrocyte phenotype demonstrating the importance 
of inflammatory priming for chondroprotection (27). The 
inhibition of catabolic activity observed in our experiments 
by the decrease of GAG release when eASCs were cocultured 
with cartilage explants could be explained by reduction of 
metalloproteinases and ADAMTS expression in chondrocytes, 
as recently reported (39). Together with reduced catabolic 
activity in an inflammatory environment, the authors also 
showed ASC-induced autophagy that is a protective mechanism 
in normal cartilage, which is downregulated with OA (40). 
We also provided some evidence that eASCs participated to 
subchondral bone remodeling in  vivo as suggested by OPG 
downregulation in the sera of mice with CIOA after treat-
ment. Decreased levels of OPG could be related with increased 
osteoclastogenesis and resorption of bone sclerosis, which is 
one characteristic of OA. Indeed, in humans, presence of 
subchondral bone osteoblasts with low and high OPG levels 
was proposed to reflect different stages of attempts to repair the 
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damaged tissue in this disease: an increase in bone resorption 
followed by bone formation (41).
Finally, the finding that IFNγ-pretreatment improved eASCs 
efficiency in vivo confirmed the importance of ASC priming by 
inflammatory signals to exert a full activity. Of importance, we, 
therein, demonstrated a similar efficacy for 2 × 104 IFNγ-primed 
eASCs and 2 ×  105 naïve eASCs highlighting the possibility to 
enhance the therapeutic potential of eASCs with low anti-inflam-
matory activity. This is relevant for autologous MSC-based thera-
pies, where cells from diseased or old animals could be altered in 
their suppressive function (42). It may also be of interest to reduce 
the number of MSCs required per subject and, therefore, the cost 
of good manufacturing practice (GMP)-grade production. The 
data further suggested the importance of ASC pretreatment to 
overcome absence or low level of in  vivo priming. Indeed, the 
immunoregulatory function of MSCs is highly plastic. MSCs 
can be rendered immunosuppressive in the presence of strong 
inflammation, while weak inflammation causes MSCs to enhance 
the immune response (43). Different responses of MSCs to dif-
ferent levels of local inflammation will, therefore, influence MSC 
activity, which may explain the different outcomes observed in 
various pathologies or following diverse timing of injection for the 
same disease (21). Indeed, pretreatment of MSCs with IFNγ has 
already been shown to significantly increase therapeutic effects 
in mice suffering from graft-versus-host disease or hepatitis (44, 
45). Such pretreatment approaches may mimic the pathological 
inflammatory environments and avoid risks of unresponsiveness. 
This has still to be validated in clinical trials as a way to improve 
MSC-based clinical therapies.
In conclusion, we reported that IFNγ-pretreatment of eASCs 
greatly improved their therapeutic efficacy in terms of immuno-
suppressive and chondroprotective functions for OA treatment. 
We also demonstrated the relevance of using the CIOA mouse 
model to evaluate the role of naïve or pretreated xenogeneic 
eASCs in a cost-effective way before extrapolation to an equine-
specific OA model we have recently developed (2).
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